The Autism Impact Fund (AIF), whose mission is to revolutionize the status quo for diagnosing, treating, and living with autism through a venture capital model, invested in seven growth and early-stage companies. AIF seeks to accelerate the development and delivery of emerging technologies, translational science and innovative services to help individuals with autism reach their full potential. The financial terms of each investment were not disclosed.
The investments were in the following companies.
- Axial, which is a clinical-stage biopharmaceutical company focused on developing a pipeline of gut-restricted small molecule agents intended for the treatment of autism, other central nervous system disorders, and cancer.
- BioROSA, which is developing an objective blood test for diagnosing autism.
- Floreo, which provides a range of behavioral therapies through a telehealth-enabled virtual reality platform.
- Joshin, which is a digital platform that connects employers and families with special needs to qualified caregivers through an experience tailored to their goals.
- SpectrumAi, which is modernizing and democratizing access to high-quality autism treatment
- Suggestic, which is an AI-driven platform for developers that integrates personal health data, provider recommendations, and tailored nutrition support to deliver actionable health journeys for end-users
- Yamo Pharmaceuticals, which is a drug discovery company developing a therapeutic for core autism symptoms
AIF’s creation is the culmination of a multi-year planning process spearheaded by leaders in the scientific and investment community with a desire to change the framework for innovation that has historically relied on non-profit research investment to support change. Led by Chris Male and Rob Sarrazin as co-managing partners, AIF is unique in its foundation, focused on investment areas that can provide strong returns while supporting a significantly underserved health care area. AIF also believes this model can be further scaled and applied more broadly to address mental health and other complex chronic conditions. The fund makes direct investments across diverse sectors and stages of financing.
This was reported by Autism Impact Fund on November 10, 2021.
Contact information: Christopher Male, Co-Founder and Managing Partner, Autism Impact Fund, 1391 Fern Avenue, Orlando, FL 32814; (407) 212-2738; Website: https://autismimpact.fund/contact/